-
30-07-2014, 04:08 PM
#8511
Originally Posted by Mista_Trix
This crap (from both sides) is getting really boring to read guys.
Play the ball not the man, the rest of us are pretty sick of it - and its doing a great job of clogging up the thread.
This thread is actually only 10 pages if you cut out all the cr#p. But 70:1 cr#p posts:good posts isn't bad right, right?!
-
30-07-2014, 04:24 PM
#8512
Originally Posted by MAC
That’s really very low, I always wonder how much they discount for sentiment in creating a ‘price target’. But good on them for having a go and for being brave enough to go first.
I don't think $1.10 is low.. I can no longer be bothered doing the maths but that is a ridiciously high price to sales ratio so I'm not sure why anyone would want to pay so much for such an uncertain sales trajectory.
It may take years to get to 20,000 units let alone the 285k or so that they would need to get to USD $100m in sales. Why pay such a premium for such a high level of risk?
On a side note, i'm not sure why everybody is harping on about institutional investors. Firstly i'm sure NZ institutional investors knowledge of biotech is limited at best. Secondly institutions don't always get it right, either in terms of picks or timing.
Truth is like poetry. And most people f*cking hate poetry.
-
30-07-2014, 04:36 PM
#8513
If as I understand, the FB valuation at $1.10 assumes a delivery of profitability and $100M in revenues much later than what PEB are presently projecting, then that may well be a fair and conservative approach for FB lay cliental at this juncture, particularly as it’s the first analysts report off the block.
It’s a matter now of tracking progress against a curve.
What it does do though I think black knat, is provide room for positive upside surprises if PEB are on schedule against their goals, or rather not as delayed as FB have set as a benchmark expectation.
I don’t work to P/S ratios, they just mislead, there are other pertinent variables and they are too coarse to be meaningful.
Last edited by MAC; 30-07-2014 at 04:47 PM.
-
30-07-2014, 05:17 PM
#8514
Forbar reckon $1.10, that's good
The soon to be released Edison report (commissioned by a few major investors I hear) will be between $1.50 and $1.70
For what's it worth my DCF valuation after pushing everything out a few years and adding in a few more expenses for this year is still around the $1.00 mark
No news is often good news.
PEB management just getting on with it and drumming up support to make the dream happen
So low 70's still a good entry (sub 70 was better)
Reckon it will be close to a $1.00 by end of August
And don't forget what happens if there a surprise announcement - we must be due for one
-
30-07-2014, 05:32 PM
#8515
And a strong finish to the day bodes well for the rest of this week
Onwards and upwards
-
30-07-2014, 05:39 PM
#8516
Originally Posted by MAC
If as I understand, the FB valuation at $1.10 assumes a delivery of profitability and $100M in revenues much later than what PEB are presently projecting, then that may well be a fair and conservative approach for FB lay cliental at this juncture, particularly as it’s the first analysts report off the block.
It’s a matter now of tracking progress against a curve.
What it does do though I think black knat, is provide room for positive upside surprises if PEB are on schedule against their goals, or rather not as delayed as FB have set as a benchmark expectation.
I don’t work to P/S ratios, they just mislead, there are other pertinent variables and they are too coarse to be meaningful.
I accept that but there may be far more 'slippage' in sales than even Forbar are expecting, which is relatively commonplace in this industry in which there generally are clear winners and a sea of dead losers.
Presuming it all works out though 70-90c probably isn't a half bad entry
Truth is like poetry. And most people f*cking hate poetry.
-
30-07-2014, 05:46 PM
#8517
Member
Originally Posted by black knat
Forbar have commenced coverage with a price target of $1.10.
Thanks; I was wondering why it did so well today!
Originally Posted by Whipmoney
I don't think $1.10 is low.. I can no longer be bothered doing the maths but that is a ridiciously high price to sales ratio so I'm not sure why anyone would want to pay so much for such an uncertain sales trajectory.
Is the current price to sales ratio worth mentioning? I don't know that it has a lot of value in terms of it being used as a metric at this stage?
-
30-07-2014, 05:49 PM
#8518
Originally Posted by winner69
Good one - so now you can see how PEB shareprice could go the RAK way
Careful, W69 - you are going to get accused of being a down ramper soon.
PS. Time to change comparison chart to that of DIL to show how DIL charged upwards 2000% from 40c to $8.00?
Last edited by Balance; 30-07-2014 at 06:14 PM.
-
30-07-2014, 05:51 PM
#8519
-
30-07-2014, 07:29 PM
#8520
Originally Posted by moosie_900
You and Forsyth Barr can try and pump PEB all you want, sales are the driver here and until I see WAY more I'm going nowheree near the bull side.
I remember a certain insto called for $6.70 DIL as well after the SP had plummetted. That wasmany, many moons ago. Analyst reports can be very wrong sometimes, and shareholder faith is a VERY hard thing to get back once its gone...
Hardly pumping, Moosie.
Simply alerting a trader like yourself to the change in tone.
Surely as a trader that's what you watch out for, right?
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks